<DOC>
	<DOCNO>NCT00723294</DOCNO>
	<brief_summary>This phase II trial study well cryoablation therapy work treat patient invasive ductal breast cancer . Cryoablation kill tumor cell freeze . This may effective treatment patient invasive ductal breast cancer .</brief_summary>
	<brief_title>Cryoablation Therapy Treating Patients With Invasive Ductal Breast Cancer</brief_title>
	<detailed_description>This phase II non-randomized exploratory study . All fully eligible registered patient undergo image mammography , ultrasound , breast MRI . Patients undergo complete surgical resection primary tumor . The primary secondary objective study describe . OBJECTIVES : Primary - To determine rate complete tumor ablation patient treated cryoablation , complete tumor ablation define remain invasive situ carcinoma present upon pathological examination target lesion Secondary - To evaluate negative predictive value MRI post-ablation set determine residual situ invasive breast carcinoma - To describe adverse event associate cryoablation - To prospectively gather pain assessment data cryoablation surgical resection - Explore technical variable may affect success cryoablation</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Unifocal primary invasive ductal breast carcinoma diagnose core needle biopsy . NOTE : Patients lobular carcinoma , multifocal and/or multicentric ipsilateral breast cancer , multifocal calcification , DCIS microinvasion NOT eligible . Patients contralateral disease remain eligible . 2 . No history en bloc open surgical biopsy and/or lumpectomy diagnostic/treatment index breast cancer . Note : Prior rotational and/or vacuumassisted core biopsy permit significant distortion see image could obscure visualization detection residual disease MRI , visualization cancer ultrasound cryoablation procedure . 3 . Tumor size ≤ 2.0 cm great diameter . Specifically , tumor must measure ≤ 2.0 cm axis parallel treatment probe ≤ 1.5 cm axis antiparallel treatment probe . Largest size measure require scan ( mammogram , ultrasound MRI ) use determine eligibility . 4 . Tumor enhancement prestudy MRI . 5 . Tumor &lt; 25 % intraductal component aggregate . NOTE : The percent intraductal component patient 's diagnostic biopsy must available prior registration . If biopsy pathology report contain percent intraductal component , rereview pathology slide creation report addendum notetofile review pathologist require . 6 . No prior plan neoadjuvant chemotherapy breast cancer . 7 . Nonpregnant nonlactating . Patients childbearing potential must negative serum urine pregnancy test . NOTE : Perimenopausal woman must amenorrheic &gt; 12 month consider childbearing potential . 8 . Adequate breast size safe cryoablation . Male breast cancer patient female breast cancer patient breast small allow safe cryoablation eligible minimal thickness breast tissue lend cryoablation . NOTE : For patient breast implant , treat physician must document adequate distance exist lesion implant ensure ablated lesion contact jeopardize implant . 9 . Patients prior insitu invasive breast carcinoma eligible prior carcinoma occur contralateral breast . Patients prior insitu invasive carcinoma ipsilateral breast eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>invasive ductal breast carcinoma</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
</DOC>